Phase 2 Lung Cancer Trial, Recruiting NCT06121505 Sponsor: Sichuan University Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06121505
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 years old
  • People who have been confirmed through tissue or cell testing to have squamous cell lung cancer, with imaging showing the cancer is locally advanced or has spread and cannot be surgically removed or treated with a standard combination of chemotherapy and radiation (Stage IIIB–IV)
  • People who have at least one tumour that can be measured on a scan, according to standard medical measurement guidelines
  • People who are able to provide a sufficient tissue or cell sample of acceptable quality so that a protein called PD-L1 can be tested
  • People who have not previously received any systemic (whole-body) cancer treatment for their locally advanced or metastatic disease

Who may not be able to join:

  • People whose cancer is a type called small cell lung cancer (SCLC), including cancers that are a mix of SCLC and non-small cell lung cancer
  • People whose cancer is a type called lung adenocarcinoma, including cancers that are a mix of adenocarcinoma and squamous cell lung cancer
  • People whose cancer has certain specific genetic features — known as EGFR sensitive mutation, ALK fusion positive, or ROS1 fusion positive (confirm with trial site)
  • People who have previously been treated with certain immune-based therapies, including anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or similar medicines that affect how the immune system's T cells respond to cancer
  • People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: You Lu, MD, West China Hospital

Phone: +86 189 8225 1798

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Sichuan University
Registry
ClinicalTrials.gov
Start date
1 March 2024
Est. completion
28 February 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

objective response rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov